Shares of Swiss pharmaceutical giant Roche (OTCQX:RHHBY) saw their strongest monthly gain since 1997 in November, fueled by optimism around an experimental breast cancer drug and positive trial results.
The stock gained 19% last month after Roche said its giredestrant medicine helped women with a form of early breast cancer. Additionally, news of two late-stage trials showed that a multiple sclerosis drug could work for most forms of the disease.
As such, Seeking Alpha investing group leader Edmund Ingham upgraded Roche to Buy, citing strong 2025 performance, a robust pipeline, and attractive valuation metrics.
While RHHBY faces major patent expirations, new launches like Phesgo, Helimbra, and Vabysmo, plus a deep pipeline, can offset losses, Ingham added.
He further noted that Roche's obesity assets, for example, could drum up billions, or potentially even tens of billions, of revenues in the 2030s - provided they are approved with a similar safety and efficacy profile to Novo Nordisk's (NVO) semaglutide and Eli Lilly's (LLY) tirzepatide - better known as Ozempic / Wegovy and Zepbound / Mounjaro.
Furthermore, the company has lifted its full-year guidance for per-share core earnings growth to a high single- to low double-digit range from the prior outlook of a high single-digit rise in currency-adjusted terms. However, the company reiterated its annual sales forecast, implying mid-single-digit growth.
YTD, the stock is up 37%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.